Catalog No.
DHC12501
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Concentration
0.63 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05067
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MABT5102A, RG7412, CAS: 1095207-05-8
Clone ID
Crenezumab
The amyloid hypothesis of Alzheimer's disease at 25 years, PMID: 27025652
Drug candidates in clinical trials for Alzheimer's disease, PMID: 28720101
Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease, PMID: 31969177
Passive antiamyloid immunotherapy for Alzheimer's disease, PMID: 32040044
Pathways Connecting Late-Life Depression and Dementia, PMID: 32231570
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks, PMID: 32568196
Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid, PMID: 31168802
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials, PMID: 33321511
Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric Aβ, PMID: 31787113
Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin, PMID: 27996029
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease, PMID: 29695589
Computational Investigation of Gantenerumab and Crenezumab Recognition of Aβ Fibrils in Alzheimer's Disease Brain Tissue, PMID: 32991803
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE), PMID: 30231896
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort, PMID: 29955659
Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models, PMID: 26467270
Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies, PMID: 28924036
Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?, PMID: 24803227
Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers, PMID: 34347883
Mechanistic Modeling of Soluble Aβ Dynamics and Target Engagement in the Brain by Anti-Aβ mAbs in Alzheimer's Disease, PMID: 32116192
N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer's disease, PMID: 32497293
Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan, PMID: 30090848
Therapeutic strategies for Alzheimer's disease in clinical trials, PMID: 26721364
Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward, PMID: 24490853
Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies, PMID: 28066098
Alzheimer disease immunotherapeutics: then and now, PMID: 25483498
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?, PMID: 24445401
Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide, PMID: 29663816
Developing Disease-Modifying Treatments in Alzheimer's Disease - A Perspective from Roche and Genentech, PMID: 29181492
Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?, PMID: 24981190
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial, PMID: 32418361
Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease, PMID: 31647950
Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies, PMID: 25880481
Can Anti-β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?, PMID: 33575481
Critical Appraisal of Amyloid Lowering Agents in AD, PMID: 34110536
Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed?, PMID: 23299379
The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial, PMID: 29405233
Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity, PMID: 33675750
Alzheimer's drugs take a new tack, PMID: 22962697
Pioneering Alzheimer's study in Colombia zeroes in on enigmatic protein, PMID: 29595782
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease, PMID: 33831607
Colombia at the centre of preclinical AD research, PMID: 22710749
Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies, PMID: 26433971
LIFTING THE CURSE OF ALZHEIMER'S, PMID: 26336711
Alzheimer's research. Stopping Alzheimer's before it starts, PMID: 22903991
Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease, PMID: 33938131
Genentech's Alzheimer's antibody trial to study disease prevention, PMID: 22871696
Sting of Alzheimer's failures offset by upcoming prevention trials, PMID: 22935790
US government sets out Alzheimer's plan, PMID: 22622544
For research use only. Not for human or drug use.
